权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Effects of Prenatal Opioid Exposure on Infant Autonomic Physiology

产前阿片类药物暴露对婴儿自主生理学的影响

基本信息

批准号：
10266050
负责人：
Alexandra Tabachnick
金额：
$ 2.03万
依托单位：
UNIVERSITY OF DELAWARE
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-06-01 至 2021-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10266050
关键词：
Accounting Address Affect Age-Months Applications Grants Area Attention Autonomic nervous system Buffers Cardiac Child Rearing Clinical Code Data Development Economic Burden Environment Exposure to Face Future Goals Helping to End Addiction Long-term Infant Infant autonomic nervous system Intervention Interview Investigation Life Measures Medicaid Medical Mental Health Methadone Methodology Mothers Nervous System Physiology Opiate Addiction Outcome Physiology Play Pregnancy Pregnant Women Prevalence Psychophysiology Public Health Randomized Controlled Trials Recovery Regulation Reporting Research Rest Risk Scientist Sinus Arrhythmia Standardization Time TimeLine Tobacco Training United States National Institutes of Health Woman Women&apos s Group caregiving community based research dosage fetal opioid exposure fetal substance exposure health care service utilization indexing infant outcome interest longitudinal design medication-assisted treatment neonatal period non-opioid analgesic opioid exposure opioid use opioid use disorder physical conditioning postnatal programs prospective resilience respiratory response social stressor sociodemographic variables standard of care substance use treatment planning

项目摘要

PROJECT SUMMARY/ABSTRACT The increasing prevalence of opioid dependence among pregnant women is a major public health concern, partially because prenatal opioid exposure is associated with a range of adverse neurodevelopmental and medical outcomes for infants. Prenatal opioid exposure has been associated with atypical autonomic nervous system (ANS) functioning in the first days of life, but there have been few investigations later in development. Further, although prenatal opioid exposure is frequently accompanied by exposure to other substances, few studies account for polysubstance exposure. Thus, the unique effects of prenatal opioid exposure on autonomic functioning are not well understood. [In addition, although the postnatal caregiving environment may moderate the effect of opioid exposure on infant functioning, parenting quality as a moderator of prenatal opioid exposure has received relatively little attention.] Autonomic dysregulation has important implications for physical and mental health, so determining the degree to which prenatal opioid exposure affects infant ANS functioning, and identifying modifiable moderators of this effect, are critical steps to inform treatment. Consistent with NIH’s programmatic interests (i.e., the HEAL Initiative), the proposed study will assess the effect of prenatal opioid exposure on infant ANS regulation at six months of age [and will examine parenting quality as a modifiable moderator of this effect.] As part of a larger randomized controlled trial, the proposed study will [examine the effect of opioid exposure within a group of women receiving medication-assisted treatment for opioid dependence (e.g., methadone).] Substance exposure information will be collected with a validated interview (the Timeline Followback) with mothers during pregnancy and when infants are six months old. [Parenting quality will be assessed via observational coding of a video-recorded free play activity when infants are six months old.] Two indicators of infant ANS functioning will also be collected at six months: respiratory sinus arrhythmia (RSA) and cardiac pre-ejection period (PEP). Infant RSA and PEP will be measured at rest and in response to a social stressor (the still-face paradigm). The proposed study will determine the degree to which prenatal opioid exposure is related to infant autonomic activity at six months of age, [and will examine parenting quality as a moderator of this effect.] Because receiving medication-assisted treatment (MAT) during pregnancy is the current standard of care for opioid-dependent pregnant women, understanding the impact of prenatal opioid exposure, and identifying malleable moderators of this effect, are critical steps to identify treatment targets and inform treatment planning for women and their infants. The proposed plan includes advanced training for the applicant in ANS, prenatal substance exposure, parenting, and community-based research.

项目总结/文摘